Analyst Ratings for Bio-Rad Laboratories Inc. Cl A (BIO)

Updated: 2017-07-29

Shares of Bio-Rad Laboratories Inc. Cl A (NYSE:BIO) have received a consensus rating of Buy from Wall Street analysts. About 30 days ago, BIO was issued an average rating of Overweight.

Of the 4 analysts covering the stock, 3 gave it a buy rating, 1 gave an overweight rating, 0 issued a hold rating, 0 gave an underweight rating, and 0 issued a sell rating. Compared to three months ago, there has been an increase of 2 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

Investment analysts gave a few price targets for BIO. The maximum price target given was 275, implying a possible profit of 16.35 percent. The most pessimistic analyst gave a price target of 245, implying a possible loss of 3.66 percent. It is advisable to not rely only on price targets or ratings, as these can be biased for some stocks.

In the last 30 days, analysts have changed their quarterly earnings estimates upwards by an average of 14.42 percent. That number becomes -16.21 percent if we expand the time horizon to include the past 3 months instead of just one. On the other hand, earnings estimates for the fiscal year have been revised upwards by 3.5 percent, as compared to a month ago. If we look at the last 90 days instead, we find a net average change of 6.68 percent in FY estimates.

Investors like to see analysts making revisions in the same direction, as that raises confidence in the revisions. 1 analysts have revised their quarterly estimates upwards in the past 30 days, which can be compared to the 0 analysts that decreased their estimates. During this time, 1 analysts made positive revisions in their estimates for this fiscal year's earnings, compared to 0 analysts that revised their FY estimates downwards.

The growth rate of BIO's earnings is estimated by analysts to be 215.57 percent. Another measure frequently examined by investors is the PEG ratio. A lower PEG ratio is favorable, because people typically see that as an indicator of higher growth relative to stock price. PEG ratios below 1 are often considered desirable, even though it may be more relevant to compare the ratio to that of a firm's competitors. BIO has a PEG ratio of 1.17.

In the trailing 52-weeks, BIO hit 239.91 at the highest peak, while it's lowest trading point was 143.39. The current market price is above the trailing year's low by 64.84 percent, and 1.48 percent lower than its 52-week high. BIO has a price/earnings ratio of 251.45. Investors typically compare the P/E ratio to a company's peers in the industry. The BIO value stock report compares BIO to some of its peers using value stock charts. The stock has a market capitalization of $7.03 billion. BIO is estimated to release their earnings results for the quarter on 0000-00-00, days from today.